Skip to main content
. 2017 Apr 7;16:143. doi: 10.1186/s12936-017-1775-2

Table 3.

Parasitological responses by study

Site Year Drug Enrolled n Day 3 Pos. n (%) Non-PCR corrected PCR corrected
Excl./loss LPF ACPR n (%) Excl./loss LPF ACPR n (%) KM cure rate % (95% CI)
Muse 2011–12 AL 55 4 (7.3) 3 0 52 (100) 3 0 52 (100) 100 (n/a)
Muse 2011–12 AS + MQ 45 1 (2.2) 1 0 44 (100) 1 0 44 (100) 100 (n/a)
Tamu 2012 AL 74 4 (5.4) 2 2 70 (97.2) 2 2 70 (97.2) 97.3 (89.6–99.3)
Tamu 2012 AS + MQ 74 0 (0) 4 1 69 (98.6) 4 1 69 (98.6) 98.6 (90.3–99.8)
Tabeikkyin 2014 AL 75 0 (0) 5 2 68 (97.1) 7 0 68 (100) 100 (n/a)
Tabeikkyin 2014 DP 72 0 (0) 2 0 70 (100) 2 0 70 (100) 100 (n/a)
Tamu 2014 DP 75 0 (0) 3 2 70 (97.2) 5 0 70 (100) 100 (n/a)

No early treatment or late clinical failures recorded

LPF late parasitological failure, ACPR adequate clinical and parasitological response, KM Kaplan-Maier, CI confidence interval